Two new medications, called lecanemab and donanemab, have shown success in clinical trials in slowing down Alzheimer’s disease. These are known as disease-modifying treatments and have been licensed ...

Javier Segovia, vice president of sales and services for the UK and Europe, said: “RadioRA 3 makes this suite of state-of-the ...